Global /Taiwan /Healthcare /Drug Manufacturers - General /4166

Orient Pharma Co., Ltd.

4166

• TPEX: 4166 • Delayed

25.80TWD -2.6%

0.8202 USD

As of 6 June 2026, Orient Pharma Co., Ltd. has a market cap of $187.89M USD, ranking #21489 globally and #1003 in Taiwan. It ranks #1925 in the Healthcare sector, and #695 in the Drug Manufacturers - General industry.

Global Rank

21489

Country Rank

1003

Sector Rank

1925

Industry Rank

695

Key Stats

Market Cap

$187.89MUSD

5.91B TWD

Enterprise Value

$174.17MUSD

5.48B TWD

Revenue (TTM)

$44.52MUSD

1.4B TWD

EBITDA (TTM)

$11.94MUSD

375.51M TWD

Net Income (TTM)

$6.63MUSD

208.44M TWD

EBITDA Margin

27%

Profit Margin

15%

PE Ratio

29.3

PS Ratio

4.2

PB Ratio

2.3

EV/EBITDA

13.9

Company Profile

Country (HQ)

Taiwan

Sector

Healthcare

Industry

Drug Manufacturers - General

CEO

Chun-Tong Huang open_in_new

Employees

173

Founded

2008

Website

oppharma.com open_in_new

warningChart data may be delayed

1d	1w	1m	3m	6m	YTD	1y	3y	5y
-2.6%	1.2%	-1.7%	-4.4%	-0.8%	-1.3%	-14%	12%	57%

News

Markets

Exchange	Ticker	Price	Quotes
Taipei Exchange (TPEX) MIC: ROCO PRIMARY	4166 友霖生技醫藥股份有限公司 ISIN: TW0004166004 Shares Out.: Shares Outstanding: 243.035M¹ Shares Float: 125.453M² TV: TradingView: TPEX: 4166 SA: Stock Analysis: TPEX: 4166 YF: Yahoo Finance: 4166.TWO GF: Google Finance: TPEX: 4166 BA: Barron's: 4166 MS: Morningstar: ROCO: 4166	25.80 TWD	TV: TradingView: TPEX: 4166 SA: Stock Analysis: TPEX: 4166 YF: Yahoo Finance: 4166.TWO GF: Google Finance: TPEX: 4166 BA: Barron's: 4166 MS: Morningstar: ROCO: 4166

¹Market cap is calculated using shares outstanding.

²Float shares are publicly tradable shares, excluding insider-held stock.

About Orient Pharma Co., Ltd.

Orient Pharma Co., Ltd. engages in the development of new drugs in Taiwan and internationally. It offers cardiovascular drugs, such as Pitator and Tonvasca for lipid suppression, as well as Zulitor, a lipid lowering drug; psychotropic drugs, including Trokendi XR extended, Methydur, and powder and solvent for prolonged-release suspension for injection. The company was founded in 2008 and is based in Taipei, Taiwan.

Similar Companies

Industry: Drug Manufacturers - General (Taiwan)

Name	Market Cap (USD) diff.	PE	Country
PharmaEssentia Corp. TWSE: 6446	$7.8B 245.34B TWD 4K%	48.6	Taiwan
Lotus Pharmaceutical Co., Ltd. TWSE: 1795	$1.84B 57.95B TWD 880%	12.2	Taiwan
Center Laboratories, Inc. TPEX: 4123	$925.55M 29.11B TWD 393%	3.4	Taiwan
Lumosa Therapeutics Co., Ltd. TPEX: 6535	$809.3M 25.46B TWD 331%	-	Taiwan
Oneness Biotech Co., Ltd. TPEX: 4743	$789.12M 24.82B TWD 320%	-	Taiwan
TTY Biopharm Company Ltd. TPEX: 4105	$584.14M 18.38B TWD 211%	11.8	Taiwan

Industry: Drug Manufacturers - General (Global)

Name	Market Cap (USD) diff.	PE	Country
Eli Lilly and Co. NYSE: LLY	$761.68B 405K%	38.1	United States
Johnson & Johnson NYSE: JNJ	$547.28B 291K%	26.4	United States
AbbVie Inc. NYSE: ABBV	$360.63B 192K%	97.4	United States
Roche Holding AG SIX: RO	$324.68B 256.25B CHF 173K%	19.9	Switzerland
AstraZeneca PLC LSE: AZN	$289.43B 215.59B GBP 154K%	27.6	United Kingdom
Novartis AG SIX: NOVN	$277.35B 218.9B CHF 148K%	20.5	Switzerland

chevron_leftBack